MeiraGTx Plans To Present An Update On AAV-hAQP1 Clinical Program For Treatment Of Grade 2/3 Radiation-Induced Xerostomia On June 27, 2023
Portfolio Pulse from Benzinga Newsdesk
MeiraGTx plans to present an update on its AAV-hAQP1 clinical program for the treatment of grade 2/3 radiation-induced xerostomia on June 27, 2023. The Phase 1 AQUAx clinical trial aims to evaluate the safety of the investigational gene therapy in patients who have remained cancer-free for at least five years.
June 22, 2023 | 8:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
MeiraGTx will present an update on its AAV-hAQP1 clinical program for radiation-induced xerostomia treatment on June 27, 2023, potentially impacting its stock price.
The presentation of the update on MeiraGTx's AAV-hAQP1 clinical program could potentially impact its stock price, depending on the results and progress of the trial. However, it is difficult to predict the direction of the impact without more information on the update.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100